Skip to content

Study · Randomized controlled trial · n = 58 · 2024

3 results

Impact of chronic intranasal oxytocin administration on face expression processing in autistic children: a randomized controlled trial using fMRI.

Moerkerke M, Daniels N, Van der Donck S, Tang T, Prinsen J, Yargholi E, Steyaert J, Alaerts K, Boets B

Molecular autism21 Dec 2024Cited by 4 (Europe PMC)

PMID39709442 (opens in a new tab)PMCIDPMC11662540 (opens in a new tab)DOI10.1186/s13229-024-00635-z (opens in a new tab)PepBankPUB-39709442
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In autistic children, exploratory analyses showed lower activity in the left superior temporal sulcus and inferior frontal region with oxytocin than with placebo.

    In plain wordsIn autistic children, exploratory analyses found lower activity in two face-related brain regions with oxytocin than with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseBrain activity in left superior temporal sulcus and inferior frontal region
    Study

    n = 58

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    24 IU daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    exploratory analyses (uncorrected for multiple comparisons) demonstrated decreases in brain activity in the left superior temporal sulcus (STS) and inferior frontal region in the oxytocin compared to the placebo group
    1 context sentence
    Summary · context
    Next, in the autistic children group, we implemented this fMRI face processing task in a double-blind, placebo-controlled, multiple-dose oxytocin clinical trial, to evaluate the impact of four-week repeated oxytocin administration (24 IU daily dose) on brain activity in face processing regions.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In autistic children, four weeks of oxytocin had no significant treatment effect on brain activity during face processing versus placebo.

    In plain wordsIn autistic children, oxytocin did not significantly change brain activity during face viewing compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeTreatment effect on neural face-processing activity (fMRI)
    Study

    n = 58

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    24 IU daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    Furthermore, no significant treatment effects were found in the oxytocin clinical trial.
    1 context sentence
    Summary · context
    Next, in the autistic children group, we implemented this fMRI face processing task in a double-blind, placebo-controlled, multiple-dose oxytocin clinical trial, to evaluate the impact of four-week repeated oxytocin administration (24 IU daily dose) on brain activity in face processing regions.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In autistic children given oxytocin, neural activity in the core face-processing network, amygdala and inferior frontal region fell significantly from baseline.

    In plain wordsIn autistic children given oxytocin, activity in face-related brain regions was lower than at the start.

    Peptide
    Oxytocin
    Outcome
    DecreaseChange from baseline in neural activity of face-processing network and amygdala
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    24 IU daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    change-from-baseline analyses in the oxytocin group revealed significantly reduced neural activity in the core face-processing network (STS, inferior occipital, and posterior fusiform), as well as in amygdala and inferior frontal region.
    1 context sentence
    Summary · context
    Next, in the autistic children group, we implemented this fMRI face processing task in a double-blind, placebo-controlled, multiple-dose oxytocin clinical trial, to evaluate the impact of four-week repeated oxytocin administration (24 IU daily dose) on brain activity in face processing regions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.